Mayne Pharma Group Limited announced the launch of butalbital acetaminophen (APAP) tablets 50 mg/300 mg in the United States. Butalbital / APAP is indicated for the treatment of tension headache (migraine).
Mayne Pharma will distribute the drug on behalf of its partner, Mikart Inc. which developed the product and is also manufacturing the product.
According to IMS Health, US brand sales were approximately US$27 million for the 12 months ending 31 December 2016.
Mayne Pharma’s CEO, Mr Scott Richards, said “We are very pleased to have licensed this product from Mikart, Inc, one of our strategic partners. This will be the first generic alternative to BUPAP® and will bring patients and payers improved medication affordability.”
Mayne Pharma continues to aggressively expand its product portfolio through internal product development, strategic acquisition, in-licensing and working collaboratively with partners like Mikart. Today, the Company directly markets more than 50 products and has a growing pipeline of more than 40 generic and branded drug products targeting US markets with IMS sales greater than US$6 billion.